Tango Therapeutics, Inc.
TNGX
Classifica tra le azioni
#4496
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Prezzo delle azioni
$27.18
Ultima sincronizzazione: 2026-07-31
Capitalizzazione di mercato
$3.38B
Variazione (1 giorno)
-1.41%
Variazione (1 anno)
213.86%
Paese
US
Scambia Tango Therapeutics, Inc. (TNGX)
Categoria
Healthcare
Storico del prezzo dell'azione per Tango Therapeutics, Inc. (TNGX)
Prezzo di chiusura più alto: $28.53 il 2026-07-01
Prezzo di chiusura più basso: $10.21 il 2020-09-01
Prezzo di chiusura più basso: $10.21 il 2020-09-01
Storico del prezzo dell'azione di Tango Therapeutics, Inc. dal 2020 al 2026
Andamento annuale del prezzo dell'azione
| Anno | Performance |
|---|---|
| 2026 (TTM) | 94.33% |
| 2025 | 186.22% |
| 2024 | -66.61% |
| 2023 | 25.09% |
| 2022 | -28.88% |
| 2021 | -3.27% |
| 2020 | 0.00% |
Prezzo dell'azione per aziende simili o concorrenti
| Azienda | Prezzo dell'azione | Variazione 1a% | Il paese |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $766.95 | 9.01% |
CH
|
